Pfizer has been making headlines because of its work developing a Covid-19 vaccine. On Monday and Tuesday, the company is hoping some of that buzz will rub off on its other research projects, which will be presented in a two-part investor day Monday and Tuesday.
Such meetings are a common way for companies to drum up investor interest. But Mikael Dolsten, Pfizer’s chief scientific officer, said in an interview with STAT that never before in his decadelong tenure running the company’s labs has such a meeting focused so squarely on the company’s research and development efforts, not its financial targets.
About the Author Reprints
